Skip to main content

Urinary Tract Infection Complicated

3
Pipeline Programs
3
Companies
4
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

VABOMEREApproved
meropenem-vaborbactam
Unknown Company
beta Lactamase Inhibitor [EPC]intravenous2017
2M Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
2
Meropenem-VaborbactamPhase 31 trial
VabomerePhase 31 trial
Active Trials
NCT02166476Completed550Est. Apr 2016
NCT02168946Completed77Est. Jul 2017
Labcorp
LabcorpBURLINGTON, NC
1 program
Treatment guided by the PCR resultsN/A1 trial
Active Trials
NCT06996301Completed773Est. May 2024
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
the UTI groupN/A1 trial
Active Trials
NCT06946667Completed130Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesMeropenem-Vaborbactam
Human BioSciencesVabomere
LabcorpTreatment guided by the PCR results
Integrated Biosciencesthe UTI group

Clinical Trials (4)

Total enrollment: 1,530 patients across 4 trials

NCT02166476Human BioSciencesMeropenem-Vaborbactam

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

Start: Nov 2014Est. completion: Apr 2016550 patients
Phase 3Completed
NCT02168946Human BioSciencesVabomere

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

Start: Jul 2014Est. completion: Jul 201777 patients
Phase 3Completed
NCT06996301LabcorpTreatment guided by the PCR results

Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.

Start: Jul 2023Est. completion: May 2024773 patients
N/ACompleted
NCT06946667Integrated Biosciencesthe UTI group

Resistance Characteristics and Development of Diagnostic Model for Postoperative UTI in Patients With Kidney Stones

Start: Feb 2021Est. completion: Dec 2024130 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.